ClinicalTrials.gg
RecruitingNCT06713850SHIELDUpdated Dec 3, 2024

Angioplasty With Shockwave IVL Catheter System in Femoropopliteal Lesions

An observational study in Peripheral Artery Disease (PAD) and Chronic Limb Threatening Ischemia, sponsored by Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.

Primary conditionChronic Limb-Threatening IschemiaRegistry: Peripheral Arterial DiseaseReclassifiedWhy we changed it
Registry
Peripheral Arterial Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Limb-Threatening Ischemia
Why
  1. The study's listed conditions name Chronic Limb-Threatening Ischemia, a narrower term within Peripheral Arterial Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
130
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Chronic Limb-Threatening Ischemia with a site in China — 7 open to participants now, 7 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · China.

Started
2024
with 2 others
Observational
8 of 23
5 open now
Registered
19th of 23
by date
Lead sponsor
2 of 23
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology

Among the 23 studies in Chronic Limb-Threatening Ischemia with a site in China, this one is one of 3 that started in 2024, is one of 8 observational ones, and was the 19th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

7 of the 23 studies in Chronic Limb-Threatening Ischemia with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Chronic Limb-Threatening Ischemia with a site in China, or all of them as a file.
02

Study summary

There is a lack of prospective observational studies of shockwave balloons in the treatment of moderate-to-severe calcification of the femoral popliteal artery at the international level. Therefore, in this study, we wish to set up a real-world study of shockwave balloon in the treatment of moderate-to-severe calcification to investigate the real-world efficacy of shockwave balloon in the treatment of moderate-to-severe calcified lesions.

Read the detailed description

Vascular calcification is prevalent in patients with peripheral artery disease (PAD), especially those with comorbid diabetes or chronic kidney disease. Severe calcification portends a poor prognosis and is independently associated with an increased risk of cardiovascular mortality and morbidity. Calcification may also compromise the efficacy of endoluminal therapy, leading to suboptimal vasodilatation and an increased risk of vascular complications, including restenosis, as well as entrapment, perforation, and distal embolization. The current grading of vascular calcification is based on the PACSS score, which can be categorized as mild, moderate, or severe depending on the degree of calcification and the extent of the lesion. Neither high-pressure balloon angioplasty nor plaque resection (atherectomy) significantly improves severely calcified lesions. The efficacy of these treatment modalities has also not been validated in multicenter real-world studies. Shockwave balloons have been widely used in the clinical endoluminal treatment of severely calcified lesions due to their ability to significantly disrupt calcified structures while reducing damage to the vascular intima, thereby reducing postoperative complications. The current published study Disrupt PAD III Trial (NCT02923193) of shockwave balloon treatment of calcified lesions demonstrated a lower residual stenosis rate with shockwave balloon versus balloon dilatation alone in a randomized controlled trial (RCT) (66.4% vs. 51.9%; p = 0.02), limiting the number of patients who could be treated with shockwave balloon. p = 0.02), a lower incidence of flow-limiting entrapment (1.4% vs. 6.8%; p = 0.03), and a lower rate of posterior dilation and remedial stenting (5.2% vs. 17.0%; p = 0.001); (4.6% vs. 18.3%; p \< 0.001). Shockwave balloons have been approved by the Chinese Food and Drug Administration for endoluminal treatment of severe calcification of the femoropopliteal artery, and are currently used only in larger vascular surgery centers because of their short time on the market. On this basis, we asked whether we could set up a real-world study of shockwave balloons for the treatment of moderate-to-severe calcification to investigate the real-world efficacy of shockwave balloons in the treatment of moderate-to-severe calcified lesions.

03

Conditions studied

  • Peripheral Artery Disease (PAD)
  • Chronic Limb Threatening Ischemia

Browse trials for

Keywords

  • Peripheral Artery Disease
  • Chronic Limb Threatening Ischemia
  • Severe calcification
04

In context

Chronic Limb-Threatening Ischemia Reclassified

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

This study's planned enrollment of 130 is above the median of 111 across 104 observational studies indexed under Chronic Limb-Threatening Ischemia.

Browse Chronic Limb-Threatening Ischemia studies →

Lead sponsor

Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Compared within Chronic Limb-Threatening Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Arterial Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with PAD.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

  1. Age ≥ 18 years (2) Rutherford Classification 2-5 3) Stenosis (>70% stenosis confirmed by digital subtraction angiography (DSA) imaging) or occlusion of the femoropopliteal artery, with one healthy patent outflow tract distal to the knee in continuity with a patent outflow tract below the ankle.

(4) Patients who understand the purpose of the study, participate in the experiment voluntarily, sign the form and are willing to be followed up.

  1. The guidewire needs to pass through the lesion; 6) >24 months 7) Moderately severe calcified lesions confirmed by imaging data: 8) For patients who receive intervention in both lower extremities may be enrolled in order of time of intracavitary treatment 9) For combined aortoiliac artery lesions that have undergone endoluminal revascularization to achieve flow recanalization without more than 50% residual stenosis.

Exclusion criteria

Exclusion Criteria:

  1. Patients with stroke, cerebral hemorrhage, gastrointestinal hemorrhage, or cardiac infarction within 3 months prior to enrollment (2) Patients with known allergy to heparin, aspirin, other antiplatelet drugs, contrast agents, etc.
  1. Patients who have been enrolled in medications that interfere with this clinical trial within the last 3 months or who have been treated intraoperatively with other special vascular bed preparation devices, such as plaque volume reduction devices, special balloons, and so on; 4) Pregnant and lactating women 5) Patients who are unable or unwilling to participate in this trial. 6) patients with Berger's disease 7) patients who have received arterial bypass diversion on the treated side
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
130 participants (estimated)
Patient registry
No

Interventions

  • DeviceShockwave balloons

    To evaluate the effectiveness and safety of the Shockwave intraperipheral shockwave catheter system in peripheral arterial angioplasty.

07

What researchers measure

Primary outcomes

  1. Procedural Success Rate

    Residual stenosis \<50% with no flow-limiting entrapment after study device therapy (before subsequent endovascular device therapy).

    Time frame: procedural

Secondary outcomes

  1. Primary Patency Rate

    Primary patency of target lesions at 30 days postoperatively

    Time frame: 30 days

  2. Freedom from clinically-driven target lesion revascularization(CD-TLR)

    Clinically driven target lesion revascularization is defined as target lesion revascularization performed due to target lesion diameter stenosis ≥50% and either evidence of clinical or functional ischemia (e.g., recurrent/progressive life-limiting intermittent claudication, claudication unresponsive to medical therapy, CLI) or recurrence of the clinical syndrome for which the initial procedure was performed.

    Time frame: 1 month, 3 months, 6 months, 12 months

  3. Clinical improvement

    Improvements in Rutherford grading

    Time frame: 1 month, 3 months, 6 months, 12 months

  4. Vascular quality of life questionnaire(VascuQol)

    The VascuQol was designed as a questionnaire containing five domains: pain (4 items), symptoms (4 items), activities (8 items), social (2 items), and emotional (7 items) to evaluate Health related quality of life (HRQL). Every item has seven response options, with scores ranging from 1 to 7. A total score is the sum of all 25 item scores divided by 25.And both the total score as well as the domain scores range from 1 (worst HRQL) to 7 (best HRQL).The lower the value, the poorer the quality of life.

    Time frame: 1 month, 3 months, 6 months, 12 months

  5. Remedial stenting rate

    Remedial stenting rate

    Time frame: procedural

  6. Remedial stenting rate

    Manipulation-related acute thrombosis, arterial embolism, major amputation, and all-cause mortality

    Time frame: 1 month, 3 months, 6 months, 12 months

  7. Instrument success

    Successful delivery and deployment of a single-use peripheral intravascular shockwave catheter to the intended target lesion site and successful withdrawal of the delivery system

    Time frame: procedural

  8. Incidence of Major Adverse Events at 30 days postoperatively

    a Emergency surgical hemodialysis of the target limb; b.Unplanned target limb amputation (above the ankle); c.Symptomatic thrombosis or distal embolization requiring treatment in the area of the target lesion or in the target limb as confirmed by imaging; d.Perforation or flow-limiting entrapment of the target lesion requiring treatment; cardiac death.

    Time frame: 30 days

  9. Major adverse events

    Death, unplanned major amputation of the target limb, and CD-TLR were defined as a major adverse event.

    Time frame: 1 month, 3 months, 6 months, 12 months

08

Study locations

1 of 1 sites recruiting
  • Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
09

References and documents

Individual participant data

Plan to share: Undecided — This is a multi-center real-world study and the data will be shared among several of the participating centers. For non-participants who need to use the data, consent from all participating units will be required before use.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2024; primary completion for Nov 2027, 35 months later.

Of 47 non-industry observational studies under Chronic Limb-Threatening Ischemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 60. This study's planned 35 months is close to that.

Counting every sponsor, half of 53 studies reached it within 34 months; a quarter within 22 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 3, 2024
StartEst.
Dec 1, 2024
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2028
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06713850
Lead sponsor
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Collaborators
Shanghai Zhongshan Hospital, Huashan Hospital, Xuanwu Hospital, Beijing, The General Hospital of Southern Theater Command, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, RenJi Hospital, Chengdu University of Traditional Chinese Medicine
Responsible party
Zibo Feng (Professor, Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology) — Principal investigator
First posted
Dec 3, 2024
Start date
Dec 1, 2024 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Dec 3, 2024

Study contacts

Zibo Feng, MD
Contact
fengzibo@hust.edu.cn
86-13545160302
Ye Du, DM
Contact
duye@hust.edu.cn
86-15827105515

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion